Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: ge who wrote (7177)	4/7/1998 9:14:00 PM
From: squetch	Respond to of 8116

The results you speak of, making money, have lead to a secondary benefit for BTGC. That benefit is publicity in the form of SP coverage which was sent out at least all the Fidelity brokerage people, and Individual Investor mag coverage. Plus the added benefit of being "one of the few biotechs making any money." BTGC's product revs were 11 mill, 21mill, 40.4mill, and 53.7 mill in 94, 95, 96, and 97 respectively. In 94 the range is ~2 to 6 by eyeball. Respectfully ge, I don't see BTGC today as a good comparison to CYTO tomorrow.

To: ge who wrote (7177)	4/8/1998 6:20:00 AM
From: robert heisman	Read Replies (1) \| Respond to of 8116

Ge, you are right. The problem is that Cytogen disappointed wall street years back and they have never forgotten that. Now that they are "down" they will not let them back up "in my opinion" we shall see. Cyto did not recover when things were made out to be doing well in the past 18 - 24 months. Even if they should show a profit the street will go on past reputation and take a LLOONNGG wait and see attitude. $9.00 for Cyto I don't think in my life time and I'm only 52. I wish you luck and only success with CYTOGEN. Bob Heisman